Chronic Myelocytic Leukemia and Interferon : Pathophysiological, Clinical and Therapeutical Aspects /

Bibliographic Details
Main Author: Huhn, Dieter, 1935-
Corporate Author: SpringerLink (Online service)
Other Authors: Hellriegel, Klaus Peter, Niederle, Norbert
Format: eBook
Language:English
Published: Berlin, Heidelberg : Springer Berlin Heidelberg, 1988.
Subjects:
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Cytogenetic Findings in Myeloproliferative Disorders
  • Molecular Analyses of Chronic Myelocytic Leukemias
  • Molecular Biological Investigation in Chronic Myelogenous Leukemia Patients Undergoing Interferon Therapy
  • Effect of Recombinant Interferon-Alpha-2 on the Growth of Hematopoietic Progenitor Cells in Chronic Myelogenous Leukemia and Its Relationship to the Clinical Efficacy
  • In Vitro Effects of Recombinant Human Tumor Necrosis Factor-Alpha and Interferon-Gamma on Normal and Leukemic Myelopoiesis
  • Demonstration of Interferon-Alpha Receptors in Cultured Cell Lines and in Myeloid Cells from Patients with Acute or Chronic Myeloid Leukemia
  • Differential Regulation of Cell Membrane Receptors for Interferon-Gamma and -Alpha on Peripheral Blood Cells of Patients with Chronic Myelogenous Leukemia During Interferon-Gamma/-Alpha Therapy
  • Studies of Interferon as a Regulator on Hematopoietic Stem Cells in Chronic Myelogenous Leukemia
  • Suppressive Effect of Interferon Alpha-2b on Hematopoietic Progenitor Cells in Patients with Chronic Myelogenous Leukemia
  • Clinical Significance of Neutralizing Antibodies in Patients with Chronic Myelogenic Leukemia
  • Cytostatic Therapy of Chronic Myelogenous Leukemia: Review and Perspectives
  • In Vivo Effects of Interferon-gamma in Chronic
  • Treatment of Chronic and Acute Phase Chronic Myelogenous Leukemia with Interferon-Alpha-2b and Interferon-
  • Maintenance Therapy of Busulfan-Induced Chronic Granulocytic Leukemia Remissions with Interferon-Alpha-2b
  • Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia.